Search

Your search keyword '"Hwang, Wei-Ting"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Hwang, Wei-Ting" Remove constraint Author: "Hwang, Wei-Ting" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
45 results on '"Hwang, Wei-Ting"'

Search Results

1. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

3. Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).

4. Improving comprehensive genotyping in patients with newly diagnosed non-squamous NSCLC: Results from a prospective trial of a behavioral nudge intervention.

5. Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC Registry Study.

6. Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer.

7. Incorporation of plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer.

8. Accrual of Black participants to cancer clinical trials following a five-year prospective initiative of community outreach and engagement.

10. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

11. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

13. Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy.

22. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

24. A decision-support tool to assist muscle-invasive bladder cancer patients choosing between radical cystectomy and chemoradiotherapy.

25. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.

28. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

33. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma.

34. Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells.

35. Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer.

41. A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.

42. In Reply

43. In Reply

Catalog

Books, media, physical & digital resources